Pylarify (fluorine-18 piflufolastat) injection - BPA
Active Blanket Purchase Agreement Awarded Last action
- Contract number
- N0025922A0006
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3
- Awarding agency
-
Bureau of Medicine and Surgery
Department of the Navy, Department of Defense
- Task orders
- 5 $207,301 obligated
Award facts
- Opportunity
-
- NOTICE OF INTENT TO AWARD SOLE SOURCE BPA PYLARIFY (Fluorine-18 Piflufolastat) INJECTIONS Solicitation · N0025922N0031 · Posted Mar 4, 2022
- Combined order value
- $207,301 Current and potential, with all options
- Last date to order 91% complete
- IDV ceiling 83% used
- $250,000.00
- Maximum order
- $50,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The Defense Health Agency awarded a blanket purchase agreement to Progenics Pharmaceuticals Inc. to procure PILARIFY (PIFLUFOLASTAT F-18) injection, an imaging agent used in positron emission tomography scans to aid in the detection and localization of prostate cancer. The BPA has a potential value of $250,000 and period of performance through April 2027. Multiple firm fixed price call contracts have been placed against the BPA at various medical treatment facilities for delivery of PILARIFY units, with values ranging from approximately $10,000 to $49,000. Places of performance include New York, New York.
The originating solicitation sought to establish a five-year BPA through a sole source 8(a) award to Progenics Pharmaceuticals Inc., the only authorized distributor within 25 miles of Naval Medical Center San Diego able to provide PILARIFY due to its 110 minute half-life. The BPA aims to support the Defense Health Agency's global healthcare network and medical research programs through reliable access to this imaging agent for diagnosis and monitoring of prostate cancer.
Task orders
Quick answers
Who was awarded contract N0025922A0006?
N0025922A0006 was awarded to Progenics Pharmaceuticals Inc. by Bureau of Medicine and Surgery (Department of the Navy) on March 30, 2022.
How much is contract N0025922A0006 worth?
Orders under N0025922A0006 have obligated $207,301. N0025922A0006's own ceiling is $250,000. A single order can be worth up to $50,000.
How many orders have been placed under contract N0025922A0006?
5 orders have been placed under N0025922A0006, the latest on December 14, 2022.
Which agency awarded contract N0025922A0006?
Bureau of Medicine and Surgery (Department of the Navy) awarded N0025922A0006, with funding from Defense Health Agency (Department of Defense).
Who can order from contract N0025922A0006?
N0025922A0006 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV